BCD-178 not checked

Biocad

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
21 active
24 in total · 22 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Breast Cancer
Main trialPhase 3
“The goal of this study is to compare the efficacy and safety of BCD-178 and Perjeta as neoadjuvant therapy for HER2-positive breast cancer. Subjects with histologically confirmed diagnosis of HER2-positive invasive breast cancer (stage II-III, tumor size \> 2 cm), with no estrogen (ER) and progesterone (PR) receptors will be randomized to one of two treatment groups (BCD-178 group or Perjeta group) in a 1:1 ratio.”In the company’s words, NCT05802225 on ClinicalTrials.gov
Other names
pertuzumab
Copy of
Perjeta (Genentech)Tested side by side with the original in NCT05738993, NCT05802225

Other drugs for Breast Cancer

All 396 drugs for Breast Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials24

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 6 Jun 2025 Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Phase 1Unknown 30 Apr 2023 A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
Phase 1Ended not given A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer.
Phase 2Authorised not given A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
Phase 3Authorised not given TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER (PHATIMA)
Phase 2Authorised not given HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA
Phase 3Authorised not given A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS
Phase 2Authorised not given Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy The PHERGain study.
Phase 2Authorised not given An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer
Phase 2Authorised not given ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling
Phase 2Authorised not given InTTercePT : Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression
Phase 2Ended not given Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program)
Phase 3Authorised not given A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer
Phase 3Authorised not given The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction. The TRAP-2 study
Phase 2Authorised not given Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study
Phase 2/3Authorised not given Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to curative-intent treatment – SHAMROCK study
Phase 3Authorised not given Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)
Phase 1/2Authorised not given Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 study
Phase 4Authorised not given Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)
Phase 2Authorised not given PErsonalized TREatment of high-risk MAmmary Cancer - the PETREMAC trial
Phase 3Authorised not given Diagnostic HER2DX-guided trEatment For patIeNts wIth early-sTage HER2-positIVE breast cancer
Phase 3Authorised not given Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-POsitive Metastatic Breast Cancer with Proactive Toxicity ManagementReflecting Real-World Clinical Practice / TOP-REAL Trial
Phase 2Authorised not given Anti-HER2 treatment Discontinuation Guided by ctDNA in Patients with HER2-Positive Metastatic Breast Cancer with Sustained Disease Control: PHENIX Trial
Phase 2Authorised not given Optimization of De-EscalatiON strategies in early breast cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BCD-178

Following is part of Solo: you see every change to BCD-178 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in